MEMORANDUM "-\ ~~-;, 1350 Pennsylva ni a A ve nu e, NW, W as hington, DC > ~, ' "'

Transcription

1 Council of the District of Columbia COMMITTEE ON THE JUDICIARY & PUBLIC SAFETY MEMORANDUM "-\ ~~-;, 1350 Pennsylva ni a A ve nu e, NW, W as hington, DC > ~, ' "' TO: Nyasha Smith, Secretary of the Council " _,. FROM: Charles Allen, Chairperson, Committee on the Judiciary and Public Safety (if,_;. RE: Closing Hearing Record...-:,. ~ 1" DATE: January 3, 2018 ;~---~ "6' Dear Ms. Smith, Please find attached copies of the Notice, Agenda and Witness List, and testimony for the Committee on the Judiciary and Public Safety and the Committee on Health's joint public hearing on B , the "Opioid Overdose Prevention Act of 2017", and B , the "Opioid Abuse Treatment Act of 2017". The following witnesses testified at the hearing or submitted written testimony to the Committee on the Judiciary and Public Safety: 1. Public Witnesses 1. Dr. Earl Ettienne, Assistant Professor, Howard University School of Pharmacy 2. Dr. Richard S. Schottenfeld, Professor of Psychiatry/Chair, Department of Psychiatry and Behavioral Sciences, Howard University College of Medicine 3. Dr. Andrew Robie, Chief Medical Information Officer, Unity Health Care 4. Nekia White, Mental Health Clinician, Unity Health Care 5. Dr. Robert Keisling, Public Witness 6. Dr. Corina Freitas, Representative, Committee of Interns and Residents 7. Ibironke Hernandez, President, Nu rse Practitioner Association of DC 8. Adam Maier, Director of Housing Partnerships, Pathways to Housing DC 9. Waldon Adams, Peer Support, Coordinated Entry Team, Pathways to Housing DC 10. Kaitlyn Boecker, Policy Manager, Drug Policy Alliance 11. Tamika Spellman, Representative, The Chosen Few 12. Johanna Margeson, Legal & Advocacy Fellow, HIPS 13. Shayla Schlossenberg, Mobile Services Manager, HIPS 14. Rod Woodson, Partner & Co-Chair, DC Pratice, Holland & Knight 15. Mark LeVota, Executive Director, District of Columbia Behavioral Health Association 1

2 16. Colette Chichester, Vice President, Government Affairs- NCA, CareFirst BlueCross BlueShield 17. Laura Worby, Public Witness 18. Dr. Yavar Moghimi, Behavioral Health Medical Director, AmeriHealth Caritas D.C. 19. Justin Palmer, Vice President, Government Relations, District of Columbia Hospital Association ii. Government Witnesses 1. Karl Racine, Attorney General for the District of Columbia 2. Wayne Turnage, Director, Department of Health Care Finance 3. Dr. Tanya A. Royster, Director, Department of Behavioral Health 4. Quincy Booth, Director, Department of Corrections 5. Kelly O'Meara, Executive Director, Strategic Change Division, Executive Office of the Chief of Police, Metropolitan Police Department 6. Michelle Bonner, Executive Director, Corrections Information Council 2

3 Council of the District of Columbia COMMITTEE ON THE JUDICIARY & PUBLIC SAFETY COMMITTEE ON HEALTH REVISED NOTICE OF JOINT PUBLIC HEARING 1350 Pennsylvania Avenue, N.W., Washington, D.C COUNCILMEMBER CHARLES ALLEN, CHAIRPERSON COMMI'ITEE ON THE JUDICIARY & PUBLIC SAFETY AND COUNCILMEMBER VINCENT GRAY, CHAIRPERSON COMMITTEE ON HEALTH ANNOUNCE A JOINT PUBLIC HEARING TO CONSIDER. BILL , THE "OPIOID OVERDOSE PREVENTION ACT OF 2017" AND BILL , THE "OPIOID ABUSE TREATMENT ACT OF 2017" Tuesday, December 12, 2017, 12:00 p.m. Room 412, John A. Wilson Building 1350 Pennsylvania Avenue, N.W. Washington, D.C On Tuesday, December 12, 2017, Councilmember Charles Allen, Chairperson of the Committee on the Judiciary and Public Safety, and Councilmember Vincent Gray, Chairperson of the Committee on Health, will hold a joint public hearing to consider Bill , the "Opioid Overdose Prevention Act of 2017", and Bill , and the "Opioid Abuse Treatment Act of 2017". The hearing will take place in Room 412 of the John A. Wilson Building, 1350 Pennsylvania Avenue, N.W., at 12:00 p.m. Please note that this notice has been revised to reflect a change in date from December 14 to December 12 and a change in timefrom 1 :00 p.m. to noon. The stated purpose of Bill , the "Opioid Overdose Prevention Act of 2017", is to require the Metropolitan Police Department to provide opioid antagonist rescue kits for sworn personnel in order to prevent potential overdose deaths; to require the Metropolitan Police Department to provide training for all sworn personnel; and to allow for the voluntary surrender of opiates and drug paraphernalia at Metropolitan Police Department stations. 1

4 The stated purpose of Bill , the "Opioid Abuse Treatment Act of 2017", is to improve treatment for substance use disorders by requiring every health plan to transmit upon request a list of all in-network providers that treat opiate use disorders, along ~ith their contact information; requiring the Department of Health Care Finance to determine the feasibility of expanding opioid use disorder medication offerings in methadone clinics; requiring a study on appropriate reimbursement levels for substance abuse treatment; requiring that all currently approved forms of medication-assisted therapies prescribed for substance abuse disorders are covered without any utilization control such as a prior authorization or step therapy; requiring high-rate opioid prescribers to participate in training; requiring the Department of Corrections' Medical Director to have experience with opioid treatment; requiring that the Department of Corrections ensure individuals receiving treatment for opioid addiction prior to entering a Department of Corrections facility continue to receive that treatment; establishing a fatality review team at the Department of Behavioral Health to review all overdose deaths in the District; requiring health care facilities to make the services of at least one health care provider who is trained and authorized under federal law to prescribe opioid addiction treatment medications; and requiring hospitals to establish discharge protocols for individuals identified as having a substance abuse disorder. The Committees invite the public to testify or to submit written testimony. Anyone wishing to testify at the hearing should contact the Committee on the Judiciary & Public Safety via at judiciary@dccouncil.us or at (202) , and provide their name, telephone number, organizational affiliation, and title (if any), by close of business Thursday, December 7. Representatives of organizations will be allowed a maximum of five minutes for oral testimony, and individuals will be allowed a maximum of three minutes. Witnesses are encouraged to bring twenty single-sided copies of their written testimony and, if possible, also submit a copy of their testimony electronically in advance to judiciary@dccouncil.us. For witnesses who are unable to testify at the hearing, written statements will be made part of the official record. Copies of written statements should be submitted to the Committee on the Judiciary & Public Safety at judiciary@dccouncil.us or to Nyasha Smith, Secretary to the Council, 1350 Pennsylvania Avenue, N.W., Suite 5, Washington, D.C The record will close at the end of the business day on December 26. 2

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

74

75

76

77

78

79

80

81